Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

Industry perspectives on MDS drug development and regulatory approval

Harold Keer, MD, PhD, Taiho Oncology, Pleasanton, CA, discusses the pharmaceutical industry’s perspective on drug development and regulatory approval in myelodysplastic syndromes (MDS). Dr Keer highlights the challenges of clinical trial design, endpoint selection, development costs, and commercial viability, emphasizing the need to balance meaningful clinical benefit with regulatory requirements and investment considerations. This presentation took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, DC.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Thank you, Amir. And thanks for inviting me to give a perspective. to be clear, this is my perspective. I can’t say I represent all of industry, but I did really wanted to sort of give you a framework as to how we might think about things. my disclosures or confessions, you know, I trained in medical oncology, I’ve have done quite a bit of sort of moved into MDS, done trials have some of which have been referenced here, and I’ve worked with a number of you, so you know thanks for that...

Thank you, Amir. And thanks for inviting me to give a perspective. to be clear, this is my perspective. I can’t say I represent all of industry, but I did really wanted to sort of give you a framework as to how we might think about things. my disclosures or confessions, you know, I trained in medical oncology, I’ve have done quite a bit of sort of moved into MDS, done trials have some of which have been referenced here, and I’ve worked with a number of you, so you know thanks for that. At present as chief medical officer, I the head of research and development organization, it’s about a hundred and fifty people. So part of what I’m gonna talk about is money and funding and just to keep the lights on, you know, is i is a heavy lift. And I know it’s something that within academia, you worry about grants and everything like that. clinical research is expensive. you know, I think that as we’re talking about how are the trials designed, how long do they take and everything like that. and we all ha are accountable to somebody, whether it’s department heads, whether it’s deans, whatever and as a you know an industry, ultimately we’re trying to produce a profit. we do take some of that money and I kind of look at the commercial organization as being a necessary evil, but nonetheless, it you know, the more that they sell, the more that we can put into what we do as development. and I’ll just say that if you’re you know we are focused on the US on the one hand, FDA, but truly globally things are much, much more interconnected, and I think that a number of the slides sort of showed a world map and showed that we’ve got you know these perspectives that are coming from all over the place. And so I think with the internet it is able, we are able to sort of truly go global, but it makes things very, very complicated. so here’s kind of you know my view, not necessarily how things are represented in the speakers with this over the last four days, but you know, it’s really kind of a three-legged stool. You know, you have academia, we’re you know, interested in biology, clinical practice. And I really should include community in that as well. it’s important to involve our you know community physicians and investigators because they are treating a number of these patients. and yeah, I sort of have I’m not gonna read through the slide, but you can see sort of what the potential kind of my view, what the goals are. you know, and regulators, they sort of keep us honest and they do have public health responsibilities. They’ve got to make sure that we are you know ultimately acting in the public’s best interest. and then industry.

Yeah, so we do need to think about okay, what is the trial gonna look like? What’s the return gonna be? we have to worry about other things, manufacturing, commercial presentation. is something going to be you know a successful trial, but is it going to be commercially viable? you know, you can talk about a population. I think I did one trial now a long time ago where in the phase two we had a great response rate, and I think we treated all twenty patients in the world, and so there’s no nowhere to go from there. you know again, this is three different approaches, and just it is interesting if you look at it in terms of what are the questions being asked, what does a trial look like. You know, again, the middle there is kind of the pharmaceutical sponsor, you know, and you might notice there I talk about operational you know, enrollment speed, how are the sites performing? you are the sites, and so you know if you’re getting continually hassled by the CRA or the CRO or whatever. We are you know trying to do it. I think earlier on Friday we saw a trial design that was proposed and it had something like you know 150 sites globally where each site might enroll maybe one or two patients. That that’s really a challenge. But I’ll talk to you about why speed is so critically important. I’m not gonna improve on the discussion we just had about endpoint choice, but it is important that it leads ultimately to regulatory approval, and so showing activity.

And showing something that will result in a label, something that can be acted upon. And you know, I know our the next speaker is going to talk from a regulatory perspective, so I won’t really get on there too much. But we do have to balance what does a trial look like, what is risk tolerance, and then on top of that, from a corporate perspective, we have to look at well, what’s patent exclusivity, what is that like globally, when do you launch, how do you sequence? And I think, you know, as I as we think about the complexity, things like Inflation Reduction Act, maximum fair price, most favored nation tariffs, it makes it even more complicated. And uncertainty is something that in general investment investors and industry don’t like. but I’ll just the lot bottom bullet there is really, really important. Exclusivity, the time value of money, so money I have today, what does that mean in terms of opportunity costs? Should we do a different trial? What’s the competition gonna do? How often do we go to see trials presented and you say, well, they used the wrong control? Well, at the time that was the right control, but it took five years to enroll the trial and get the results. And so, you know, now it now it looks almost irrelevant. and of course delays add cost. So briefly, you know, I’m not gonna go through all the math and everything like that, but there’s this thing called NPV or net present value. So involved in investment decisions, and that’s kind of what do we expect. You know, if things all work out, what’s the revenue gonna be? How much is it gonna cost to do that? When’s that gonna happen? you know, there’s kind of this decay of financial money as you go along. I won’t go through all those equations, but just to say the more time goes by, the more the the the less money you have. And so you have to make decisions where do you invest money? Does it go in MDS, MPN, AML, lung cancer, and so on. and then the bottom I just have some things that I alluded to already in terms of you know their US, but they do truly impact things globally. So you have to ask the question: not only is there the potential that it’s hard, you know, you don’t get good reimbursement in Asia or Europe, but if in fact that gets used as a reference price, it may impact profits in the US. It’s very, very complicated and it’s it’s an ongoing moving target. And this is just sort of a illustration. You know, at the top, you start with say you have a drug that’s gonna sell $200 million a year. A delay may reduce that and again, depending on what assumptions you have, significantly, you start adding in decreases from IRA MFN decreases it more, you can end up in a worst case scenario of actually, you know, here you have less than half of what you thought you had.

And globally, it’s really complicated. In Europe, you can get approval, you can show that you have activity, and you may not get access. So there’s HTA, you know, health technology assessments, you have to show value, you know, which again is is another barrier. and I want to talk about Japan and the US. So, what does that mean? You know, we’ve talked a little bit in the last few days about how do we categorize and there’s low risk and high risk, and maybe that’s overly simplified. We just heard Rami talk about how are those endpoints. You know, I sort of look at it from a trial design perspective. a trial, you know, again using these as you kind of define endpoints, FDA, I think you know, would look at it this way these days. you sort of have to balance low risk, you know, if you can change disease biology, potentially you can treat for longer. Maybe that means that you have a longer time to generate revenue. However, the endpoints are a lot longer, and so maybe you have less time exclusivity and so on. So that’s that’s I think why you end up, you know, surrogate endpoints here would be very, very valuable. in higher risk, you’re looking to improve survival, but as we’ve seen with TP53 and trying to add on, it’s really you know it’s i i it it’s a tough bar to to to beat. so there’s just an illustrative low risk trial. And again I think you know you look at the sort of endpoints, this duplicates a little bit what was done there, but you end up with a smaller segment and longer follow-up versus the higher risk trial where again you may have firmer endpoints, but it’s you know as as we talk about low-hanging fruit, but it may be very, very tightly attached to the tree. so it’s really hard to you know have a positive trial. I think you know we’ve we’ve seen the frustration of you know multiple negative trials adding on to HMAs and you know, though you know we like to say, well, gosh, can’t we do better than HMAs? They’ve been out since like the 2000s. and yet adding on to them turns out to be really, really difficult. you know, and you know, there’s been lots of creative ideas here. I’m not gonna claim to have answers. I would love to say we’ve got better ideas. I do think that as we’re talking about endpoints and we’re talking about how do we compare apples to apples, how do we know that we’re having a benefit? you know, the previous talk talked about. We want to make sure that response actually translates into something that’s meaningful. from an industry perspective, we want to make decisions, and it’s much, much better if we can actually kill a program early. And so, you know, we’ve we’ve been using CR, we’ve been using MCR, because that looks good and it makes it great to tell senior management, hey, we’ve got a response and we can now go do the phase three trial. But if that’s actually gonna lead us down a bad path, that’s a that’s a problem. And so I think it benefits all of us to you know think that way. So I think, got all about 30 seconds left. I will just note that in this decision framework, we want to fund the evidence that’s gonna pay potential protect patients. So we want to make sure that we are getting the best drugs to patients. From an industry perspective, we can’t forget asset value. and so, you know, having gone through very, very quickly about NPV, does it remain attractive under various assumptions? what I have found is that really estimating that probability of success is really, really challenging. So with that.

I will thank you for your attention. I’ve been ten minutes right on time, so here we go.

AI-generated transcript. Please refer to the video as the authoritative source.

Read more...

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.